AzTrials
AzTrials

Aggressive Diffuse Large B-cell LymphomaPhase 2CLEARNCT07197307

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2 study testing Loncastuximab Tesirine and Epcoritamab in people with Aggressive Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (HGBL), run by Universität Münster at 34 sites in Germany.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Loncastuximab Tesirine and Epcoritamab
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
34 sitesGermany
Study dates
31 Oct 2025to 30 Apr 2030
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Disease:
  • Subjects with histologically confirmed relapsed/refractory DLBCL based on pathology report (WHO 2022 criteria)
  • DLBCL (de novo or transformed)
  • High-grade B-cell lymphoma with MYC and BCL2 rearrangements
  • High-grade B-cell lymphoma, not otherwise specified (NOS)
  • Follicular lymphoma grade 3B
Show all 36Show fewer
  • Diagnostic biopsy performed at the time of relapse/progressive disease no longer than 3 months before study entry must be available, with sufficient material for central review and complimentary scientific analyses. CD20 expression (or a high likelihood of CD20 expression) based on immunohistochemistry should be documented prior enrollment into the study.
  • Refractory disease is defined as no remission to the last therapy. Subjects intolerant to previous therapy are excluded. Two groups of patients are eligible:
  • Progressive disease (PD) or stable disease (SD) as best response to previous therapy.
  • Complete (CR) or partial response (PR) as the best response after previous therapy, with biopsy-proven relapse occurring < 6 months after end of treatment.
  • Relapsed disease is defined as subjects achieving complete or partial remission to previous therapy, followed by biopsy-proven relapse ≥6 months after treatment completion.
  • Subjects with refractory and early relapsed (≤12 months) disease after first line anti-CD20-/anthracycline-containing therapy are eligible. Subjects with late relapsed (>12 months) disease after first line anti-CD20-/anthracycline-containing therapy can be enrolled in the study only if deemed ineligible to high dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT)) or if refuse to undergo HDCT/ASCT. Subjects relapsed/refractory to second line CAR-T cell therapy are eligible.
  • Subject must be 18 years or older.
  • Subject must be eligible to receive and in need of treatment initiation based on symptoms and/or disease burden, as assessed by the investigator.
  • Eastern Cooperative Oncology Group Performance (ECOG) status 0-2.
  • Subject must have one or more measurable disease sites defined as follows:
  • A positron emission tomography/computed tomography (PET/CT) scan demonstrating PET- positive lesion(s) AND
  • At least one measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ one measurable extra-nodal lesion (long axis > 1.0 cm) on CT scan or MRI.
  • Ability to understand and willingness to sign written informed consent. Signed informed consent must be obtained before any study specific procedure.
  • Contraception:
  • Women of childbearing potential and sexually active men must practice a highly effective method of birth control during and after the study, consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of giving informed consent until at least 7 months after the patient receives his last dose of study treatment. Men must agree not to donate sperm from the time of giving informed consent until at least 7 months after the patient receives his last dose of study treatment. For female subjects, they apply for 12 months after the last dose of the study drug. A woman is considered to be of childbearing potential until becoming post-menopausal or permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Post-menopausal status is defined as no menstrual periods for a continuous 12-month period without an alternative medical cause. A post-menopausal state can be confirmed by a high follicle-stimulating hormone (FSH) level within the postmenopausal range, especially in women not using hormonal contraception or replacement therapy. The investigator or a designated associate will provide guidance to patients on achieving highly effective contraception (with a failure rate of less than 1%), such as intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, having a vasectomized partner, or sexual abstinence. Male patients are required to use condoms unless their female partner is permanently sterile.
  • Women of childbearing potential participating in the study will be required to undergo a pregnancy test using either urine or serum beta-human chorionic gonadotropin (beta-hCG) at the screening visit. A negative result is necessary for inclusion in the study.
  • Adequate baseline organ function tests collected no more than 7 days before starting study treatment:
  • Total bilirubin ≤ 1.5 times the upper limit of normal (ULN), except for patients with Gilbert syndrome, cholestasis due to hepatic hilum adenopathies or liver involvement, or biliary obstruction due to lymphoma, who may have a total bilirubin ≤ 3 times the ULN.
  • Alanine transaminase (ALT) and aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT) ≤ 2.5 times the ULN, or ≤ 5 times the ULN for patients with liver involvement by lymphoma.
  • Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m² according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. If not initially within target range, this evaluation may be repeated after at least 24 hours, either using the CKD-EPI formula or by 24-hour sampling. If the subsequent result is within the acceptable range, it may be used to fulfill the inclusion criteria.
  • Prothrombin time/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) ≤ 1.5 times the ULN, unless the patient is receiving anticoagulation (although the INR should not exceed 4.0).
  • Platelet count ≥ 75,000/mm³ without transfusion in the prior 7 days.
  • Hemoglobin ≥ 8 g/dL.
  • Absolute neutrophil count ≥ 1,000/mm3 (off growth factors at least 72 hours).
  • Left ventricular ejection fraction > 45%.
  • Concomitant Medications:
  • Subjects should not be taking any active medication known to decrease T-cell numbers or activity, or any other concurrent immunosuppressive medication, except for up to 10 mg of prednisone daily or an equivalent dose, unless it is necessary for disease control during the screening period, premedication and/or cytokine release syndrome (CRS)/ immune effector cell-associated neurotoxicity syndrome (ICANS) management within the study.
  • Subjects must not have been treated with any investigational drug within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of the study drug. They should not be currently enrolled in another interventional clinical study or have been previously enrolled in this study, unless the agent being used has been approved under emergency authorization (e.g., anti-severe acute respiratory syndrome coronavirus (SARS-CoV-2) monoclonal antibodies).
  • Acute toxicity (except alopecia, fatigue) of any prior lymphoma therapy should be resolved to Grade ≤ 1 (with the exception of prior CRS or ICANS that should be fully resolved) at study screening.
  • The subject should not have received vaccination with live-attenuated vaccines within 28 days prior to screening, and they should not be expected to require any live-attenuated vaccination during their participation in the study, including at least 3 months following the last dose of study treatment. However, vaccination with coronavirus messenger ribonucleic acid (mRNA) and adenovirus-based vaccines, which are not live-attenuated vaccines, is permitted.

Who cannot join

  • Patients who meet any of the following criteria at the time of screening will be excluded:
  • Any prior lymphoma-directed treatment, except for first-line anti-CD20-/anthracycline-containing chemoimmunotherapy or second line CAR-T cell therapy. Particularly, patients previously treated with loncastuximab tesirine and any CD3xCD20 bispecific antibody therapy are not eligible.
  • Patients with late relapse (>12 months) after first-line immunochemotherapy considered HDCT/ASCT eligible as assessed by the local investigator.
  • Known central nervous system (CNS) involvement.
  • Diagnosed or treated for any malignancy other than r/r DLBCL, HGBL or FL grade 3B within the last 3 years, except for adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, non-invasive basal cell or squamous cell skin carcinoma, adequately treated carcinoma in situ without evidence of disease, localized prostate cancer, post-radical prostatectomy with non-rising prostate-specific antigen levels < 0.1 ng/mL, cervical carcinoma of stage 1B or less, non-invasive, superficial bladder cancer or any curable cancer with a CR of > 2 years duration.
  • Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection or any known active systemic bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds). Patients with serologic markers of HBV immunization due to vaccination (HBsAg negative, Anti-HBc negative, and Anti-HBs positive) will be eligible. Subjects who are positive for hepatitis B core antibody, hepatitis B surface antigen, or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
Show all 31Show fewer
  • Cytomegalovirus (CMV)-PCR positive at baseline.
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or interfere with the feasibility to administer study drugs including active hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), history of cutaneous collagenous vasculopathy and capillary leak syndrome.
  • Concurrent treatment with another investigational agent or radiation therapy.
  • Any psychological, cognitive, familial, or social condition that, in the investigator's opinion, compromises the patient's ability to understand the patient information, give informed consent, or comply with the study protocol.
  • Participation in another clinical trial.
  • Known history of hypersensitivity and/or positive serum human anti-drug antibody (ADA) against any component of the study products or of the concomitant medication or an anti-CD19 antibody.
  • History of Stevens-Johnson syndrome or toxic epidermal necrolysis.
  • Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath; history of pericardial effusion).
  • Pregnancy or breastfeeding.
  • Use of any other experimental medication within 30 days or 5 half-lives prior to the start of the study drug (Cycle 1 Day 1).
  • Close affiliation with the investigational site, such as being a close relative of the investigator or dependent person (e.g., employee or student of the investigational site).
  • Excluded medical conditions:
  • Congestive heart failure > New York Heart Association (NYHA) class 2.
  • Unstable angina (angina symptoms at rest) or new-onset angina (begun within the last 3 months).
  • Uncontrolled atrial or ventricular cardiac arrhythmia.
  • Left ventricular ejection fraction ≤ 45%.
  • Electrocardiographic evidence of acute ischemia, coronary angioplasty, or myocardial infarction within 6 months prior to screening.
  • Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months before the start of study medication.
  • Congenital long QT syndrome or a QT corrected by Fridericia's formula (QTcF) interval of > 480 ms at screening (unless secondary to pacemaker or bundle branch block).
  • Severe chronic pulmonary disease.
  • Known clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
  • Autoimmune disease requiring immunosuppressive therapy, except for up to 10 mg prednisone daily (or equivalent).
  • Seizure disorder requiring therapy within the past 12 months. Subjects with a history of seizure disorder beyond must have a complete CNS workup.
  • Major surgery within 4 weeks of the first dose of study drugs, except for lymphoma reasons.
  • Any other co-existing medical or psychological condition that will preclude participation in the study or compromise the ability to give informed consent.

Trial locations and contacts

34 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Georg Lenz, Prof. contact

+492518347587

lenzsekr@ukmuenster.de

34 sites in 1 country

Germany34 sites, 34 recruiting

  • Universitaetsklinikum Aachen

    Aachen, 52074

    Recruiting

  • Universitaetsklinikum Augsburg

    Augsburg, 86156

    Recruiting

  • Vivantes Netzwerk fuer Gesundheit

    Berlin, 10967

    Recruiting

  • Charite Universitaetsmedizin Berlin

    Berlin, 12203

    Recruiting

  • HELIOS Klinikum Berlin-Buch

    Berlin, 13125

    Recruiting

  • Evangelisches Klinikum Bethel

    Bielefeld, 33611

    Recruiting

  • Klinikum Chemnitz

    Chemnitz, 09116

    Recruiting

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, 40225

    Recruiting

  • Universitaetsklinikum Erlangen

    Erlangen, 91054

    Recruiting

  • Universitaetsklinikum Essen

    Essen, 45147

    Not yet recruiting

  • Universitaetsklinikum Frankfurt

    Frankfurt, 60590

    Recruiting

  • Medical Center - University Of Freiburg

    Freiburg im Breisgau, 79106

    Recruiting

  • Universitaetsmedizin Greifswald

    Greifswald, 17489

    Recruiting

  • Universitaetsklinikum Halle (Saale)

    Halle, 06120

    Recruiting

  • University Medical Center Hamburg-Eppendorf

    Hamburg, 20246

    Not yet recruiting

  • St. Barbara-Klinik Hamm

    Hamm, 59073

    Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120

    Recruiting

  • Universitaet Des Saarlandes

    Homburg, 66421

    Recruiting

  • Universitaetsklinikum Jena

    Jena, 07747

    Recruiting

  • Staedtisches Klinikum Karlsruhe

    Karlsruhe, 76133

    Recruiting

  • Universitaetsklinikum Schleswig-Holstein

    Kiel, 24105

    Recruiting

  • Universitaetsklinikum Schleswig-Holstein

    Lübeck, 23538

    Recruiting

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, 55131

    Recruiting

  • Philipps-Universitaet Marburg

    Marburg, 35043

    Recruiting

  • Muehlenkreiskliniken

    Minden, 32429

    Recruiting

  • Klinikum der Universitaet Muenchen

    München, 81377

    Not yet recruiting

  • Universitätsklinikum Münster, Medizinische Klinik A

    Münster, 48149

    Evgenii Shumilov, PD, MD, +492518357106, Evgenii.Shumilov@ukmuenster.de

    Evgenii Shumilov, PD, MD

    Recruiting

  • Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

    Mutlangen, 73557

    Recruiting

  • Ortenau Klinikum

    Offenburg, 77654

    Recruiting

  • Klinikum Oldenburg

    Oldenburg, 26133

    Recruiting

  • Medizinisches Versorgungszentrum des Bruederkrankenhauses St. Josef Paderborn

    Paderborn, 33098

    Recruiting

  • Universitaetsklinikum Regensburg

    Regensburg, 93053

    Recruiting

  • Diakonie-Klinikum Stuttgart Diakonissenkrankenhaus und Paulinenhilfe

    Stuttgart, 70176

    Not yet recruiting

  • Universitaetsklinikum Ulm

    Ulm, 89081

    Recruiting

Other trials in Germany

About this study

This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.

Read the detailed description

A total of 120 patients will be included. 60 days after 20 patients have started the therapy, a safety analysis will be performed to identify early and unexpected side effects of the combination therapy. An interim analysis will be conducted 6 months after recruitment of the 50th patient to check the effectiveness of the therapy. For patients not pretreated with CAR-T cells, an additional and separate efficacy analysis will be performed after the 20th CAR-T naive patient started treatment with loncastuximab tesirine and epcoritamab and had a second response assessment (12 weeks after treatment initiation) by FDG-PET/CT (-/MRI).

Being tested
Loncastuximab Tesirine and Epcoritamab
Keywords
Loncastuximab Tesirine, Epcoritamab, Diffuse Large B-cell Lymphoma
Medical subject headings
Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Loncastuximab Tesirine and EpcoritamabDrug

    Loncastuximab tesirine:

    Loncastuximab tesirine 150 µg/kg iv for 2 cycles followed by 75 µg/kg iv on day 1 of each 21-day cycle in responding patients for 4 cycles subsequently (max. 6 cycles).

    Epcoritamab:

    Step-up dosing for epcoritamab sc will be performed, consisting of a 0.16 mg sc priming dose on day 1 of cycle 1 (day 8 of cycle 1 for loncastuximab tesirine), followed by a 0.8 mg sc dose on day 8, and full dosing with 48 mg sc on day 15. Starting from day 15, epcoritamab will be administered weekly during cycle 2-3, then once every 2 weeks during cycle 4-9, and once every 4 weeks from cycle 10 until cycle 13 (max. 13 cycles).

Study groups in NCT07197307
Study groupRoleWhat they receive
Loncastuximab Tesirine and EpcoritamabExperimentalCombination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma (DLBCL, HGBL or FL grade 3B)
Receives: Drug: Loncastuximab Tesirine and Epcoritamab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Best overall response rate (BORR)

    BORR defined as the proportion of patients with r/r DLBCL, HGBL and FL grade 3B who achieve a complete or partial remission as best response up to 12-months of study treatment according to the 2014 Lugano criteria.

    Measured: 12 months after the start of study therapy

Secondary outcomes (14)

  1. Progression-free survival (PFS)

    2-year progression-free survival (PFS) with a 95% confidence interval. PFS is defined as time from the first dose of study drug until one of the following events occurs, whichever is first: Disease progression, Relapse or Death due to any cause. Patients who have not experienced an event at the time of analysis will be censored at the most recent date of disease assessment.

    Measured: 2 years after the start of study therapy

  2. Overall survival (OS)

    2-year overall survival (OS) defined as the time from the first dose of study drug to death of any cause. Patients who have not experienced an event at the time of analysis will be censored at the last date known to be alive.

    Measured: 2 years after the start of study therapy

  3. Complete response (CR) rate

    Complete response (CR) rate measured as the number of complete remissions as best response (achieved up to 12 months) divided by the number of patients treated with at least one dose of study drug.

    Measured: 12 months after the start of study therapy

  4. Partial response (PR) rate

    Partial response (PR) rate measured as the number of partial remissions as best response (achieved up to 12 months) divided by the number of patients treated with at least one dose of study drug.

    Measured: 12 months after the start of study therapy

  5. Time to complete response

    Time to complete response measured as the time from the start of therapy to documentation of complete remission.

    Measured: from the start of therapy to documentation of complete remission

  6. Time to best response

    Time to best response (achieved up to 12 months) measured as the time from the start of therapy to documentation of the best tumor response according to type of response.

    Measured: 12 months after the start of study therapy

  7. Duration of response

    Duration of response measured as the time from documentation of tumor response (complete or partial remission) to relapse or progressive disease.

    Measured: from documentation of tumor response (complete or partial remission) to relapse or progressive disease

  8. Progression rate

    Progression rate measured as the number of progressions (observed up to 12 months) divided by the number of patients treated with at least one dose of study drug.

    Measured: 12 months after the start of study therapy

  9. Rate of relapse

    Relapse rate measured as the number of relapses divided by the number of patients included with complete or partial remission.

    Measured: From date of complete or partial remission until the date of relapse, assessed until the end of the study

  10. Biological characteristics of the lymphoma

    Outcomes of the study will be evaluated according to biological characteristics of the lymphoma.

    Measured: Screening visit (day -28 to day -1); during therapy cycles of loncastuximab tesirine and epcoritamab; end of trial, or in case of relapse/progression, or subject discontinuation, whichever comes first.

  11. Adverse Events (AEs)

    AEs that occurred in the study.

    Measured: AEs will be assessed at each study visit from start of the study until 150 days after the last administration of loncastuximab tesirine and/or epcoritamab (whichever is administered last).

  12. Serious Adverse Events (SAEs)

    SAEs that occurred in the study.

    Measured: SAEs will be assessed at each study visit from start of the study until 150 days after the last administration of loncastuximab tesirine and/or epcoritamab (whichever is administered last).

  13. Rate of treatment-related deaths

    Rate of treatment-related deaths defined as the number of treatment-related deaths during therapy or up to 2 months after the end of therapy divided by the number of patients treated with at least one dose of study drug.

    Measured: from start of the therapy to 2 months after the end of therapy

  14. Number and duration of treatment cycles and cumulative doses of loncastuximab tesirine and epcoritamab

    Number of treatment cycles received, duration of treatment cycles and cumulative doses of loncastuximab tesirine and epcoritamab.

    Measured: At each therapy cycle from start of the study therapy until the last administration of loncastuximab tesirine and/or epcoritamab (whichever is administered last).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Sep 2025
  2. Study start31 Oct 2025
  3. Primary completion30 Apr 2030 (estimated)
  4. Study completion30 Apr 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07197307
Sponsor's protocol ID
WWU23_0006
Other IDs
2023-509861-19-01, 2023
Acronym
CLEAR
Status last verified
Jul 2026
First submitted
3 Sep 2025
Last updated
30 Jul 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Loncastuximab Tesirine and Epcoritamab in people with Aggressive Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma (HGBL), run by Universität Münster at 34 sites in Germany.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 36 inclusion and 31 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 34 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Georg Lenz, Prof. (+492518347587, lenzsekr@ukmuenster.de), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Best overall response rate (BORR) (time frame: 12 months after the start of study therapy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07197307.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in